Companies › Restorbio
2 active drug programs in 3 registered trials: 3 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| Everolimus (RAD001) FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Respiratory Tract Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03373903 | Dactolisib (BEZ235) | Phase 2 | Respiratory Tract Infections | Infectious disease | May 2018 |
| NCT03373903 | Everolimus (RAD001) | Phase 2 | Respiratory Tract Infections | Infectious disease | May 2018 |
| NCT04584710 | Dactolisib (BEZ235) | Phase 2 | Covid19 | Infectious disease | Feb 2021 |
Eli Lilly Celcuity Sovargen Faeth Therapeutics Palvella Therapeutics Novartis iVascular S.L.U. Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca
WestVac Biopharma Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.